Understanding the Cryoglobulinemias

被引:18
作者
Fuentes, Alejandro [1 ]
Mardones, Claudia [1 ]
Burgos, Paula I. [1 ]
机构
[1] Pontificia Univ Catolica Chile, Dept Inmunol Clin & Reumatol, Diagonal Paraguay 362, Santiago, Chile
关键词
HCV; Mixed Cryoglobulinemia; Type I Cryoglobulinemia; gC1qR; Direct-acting antivirals; Rituximab; HEPATITIS-C VIRUS; RANDOMIZED CONTROLLED-TRIAL; MIXED CRYOGLOBULINEMIA; PERIPHERAL NEUROPATHY; PROGNOSTIC-FACTORS; CLINICAL SPECTRUM; VASCULITIS DATA; RITUXIMAB; PREVALENCE; DISEASES;
D O I
10.1007/s11926-019-0859-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of the Review Cryoglobulins are immunoglobulins with the ability to precipitate at temperatures <37 degrees C. They are related to hematological disorders, infections [especially hepatitis C virus (HCV)], and autoimmune diseases. In this article, the state of the art on Cryoglobulinemic Vasculitis (CV), in a helpful and schematic way, with a special focus on HCVrelated Mixed Cryoglobulinemia treatment are reviewed. Recent Findings Direct - acting antivirals (DAA) against HCV have emerged as an important key in HCV treatment to related Cryoglobulinemic Vasculitis, and should be kept in mind as the initial treatment in non-severe manifestations. On the other hand, a recent consensus panel has published their recommendations for treatment in severe and life threatening manifestations of Mixed Cryoglobulinemias. Summary HCV-Cryoglobulinemic vasculitis is the most frequent form of CV. There are new treatment options in HCV-CV with DAA, with an important number of patients achieving complete response and sustained virologic response (SVR). In cases of severe forms of CV, treatment with Rituximab and PLEX are options. The lack of data on maintenance therapy could impulse future studies in this setting.
引用
收藏
页数:10
相关论文
共 97 条
  • [1] Adinolfi LE, 1996, ITAL J GASTROENTEROL, V28, P1
  • [2] Ali MA, 2017, CLIN CASE REP, V5, P616, DOI 10.1002/ccr3.788
  • [3] ANDERSEN BR, 1971, CLIN EXP IMMUNOL, V9, P795
  • [4] Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia
    Antonelli, A
    Ferri, C
    Fallahi, P
    Giuggioli, D
    Nesti, C
    Longombardo, G
    Fadda, P
    Pampana, A
    Maccheroni, M
    Ferrannini, E
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2004, 97 (08) : 499 - 506
  • [5] Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients
    Antonelli, A
    Ferri, C
    Fallahi, P
    Sebastiani, M
    Nesti, C
    Barani, L
    Barale, R
    Ferrannini, E
    [J]. RHEUMATOLOGY, 2004, 43 (02) : 238 - 240
  • [6] Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy
    Banerjee, D.
    Reddy, K. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (06) : 674 - 696
  • [7] The clinical and morphologic spectrum of renal cryoglobulinemia
    Beddhu, S
    Bastacky, S
    Johnson, JP
    [J]. MEDICINE, 2002, 81 (05) : 398 - 409
  • [8] Bonnet F, 2003, J RHEUMATOL, V30, P2005
  • [9] Sjogren syndrome
    Brito-Zeron, Pilar
    Baldini, Chiara
    Bootsma, Hendrika
    Bowman, Simon J.
    Jonsson, Roland
    Mariette, Xavier
    Sivils, Kathy
    Theander, Elke
    Tzioufas, Athanasios
    Ramos-Casals, Manuel
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2016, 2
  • [10] BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3